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Abstract The forced expiratory volume in1sec (FEV1) is themost established outcomemeasure in chronic obstruc-
tive pulmonary disease (COPD).However, changes in FEV1 in response to treatment are small in relation to the repeat-
ability of the measurement and there is increasing interest in other measures including markers of lower airway
in£ammation in induced sputum, assessment of symptoms and health status using visual analogue scores, and question-
naires. Little is known about the repeatability of these measures or the safety of sputum induction in COPD.We have
assessed the safety of sputum induction in 61subjects withmoderate and severe COPDwho participated in a placebo-
controlled cross-over study.The within-subject repeatability of sputummarkers of airway in£ammation, health status
using the chronic respiratory disease questionnaire (CRQ) and symptom visual analogue scores (VAS) were estimated
fromthe data obtained frombefore and after 2 weeks of treatment with placebo. Sputuminductionwas performed on
122 occasions andwas successful resulting in a cytospin adequate to assess a di¡erential cell count in 95% of inductions.
The groupmean (SEM) FEV1was1?09 (0?05)[41?6 (2?9)% predicted] and themean (SEM) fall in FEV1after sputuminduction
was120 ml (6) and% fall10?9% (0?55%).Seveninductionswere stoppeddueto a fallin FEV1420% andat a further13 visits
the full sputuminductionprotocolwasnotcompleted due to developmentof symptoms.Thereproducibilityofmeasure-
ments, calculated by the intra-class correlation coe⁄cient, was relatively high for all indicesmeasured (0?4^0?95) with
the exceptionoftheproportionof lymphocytes (0?15) andepithelialcells (0?3).The ICCfor symptomscores andthe CRQ
domains ranged between 0?87 and 0?96. In conclusion, sputum induction is safe and the cell and £uid phase mediators
repeatable in the investigation of airway in£ammation in patients with COPD.VAS symptom scores and the CRQ are
reproducible outcomemeasures in COPD.r2001Harcourt Publishers Ltd
doi:10.1053/rmed.2001.1195, available online athttp://www.idealibrary.comon
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The forced expiratory volume in 1sec (FEV1) has long
been established as the main outcome measure in
assessing the progress or response to treatment in
patients with chronic obstructive pulmonary disease
(COPD). The FEV1 has shortcomings as an outcome
measure in COPD as most patients by de¢nition have
irreversible air£ow obstruction and any possible
response to treatment is small in relation to the
repeatability of the measurement (1). Consequently,
interest has increased in the use of other perhaps more
responsivemeasures.Received 3 May 2001, accepted in revised form 6 August 2001and
published online17 October 2001.
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for Lung Health,Department of Respiratory Medicine,Glen¢eld
Hospital, Leicester LE3 9QP,U.K.E-mail: chris.brightling@uhl-tr.nhsCOPD is associated with sputum (2) and bronchial
biopsy (3) evidence of neutrophilic airway in£ammation
and the extent of this in£ammation as re£ected by the
induced sputum neutrophil di¡erential count inversely
correlates with the FEV1and decline in FEV1 (2,4).These
observations are in keeping with a causal relationship
between neutrophilic airway in£ammation and disease
progression in COPD, and suggest that assessment of
markers of neutrophilic airway in£ammation might be a
meaningful outcome measure in COPD. In asthma
sputum induction is widely used and it has been estab-
lished as safe and sputum di¡erential cell counts and
supernatant concentrations are valid and repeatable
(5^7). In COPD the repeatability of di¡erential cell
counts and safety (8,9) of sputum induction in patients
with chronic obstructive pulmonary disease (COPD) is
less clear. Sputum induction with hypertonic saline is a
potential bronchoconstrictor and thus there have been
1000 RESPIRATORYMEDICINEsome concerns aboutitsuse in subjectswho alreadyhave
moderate or severe air£ow obstruction.
Patients with COPD have signi¢cant morbidity (10).
Disease-speci¢c health status questionnaires have
been developed, which have been shown to be valid,
repeatable and responsive in patients with COPD
(11^13). Symptom visual analogue scores have been used
in a number of clinical settings particularly in the
assessment of pain (14), but their possible role as an
outcomemeasure in COPD is uncertain.
We have used data from a recent cross-over,
placebo-controlled trial (15) to assess the safety of
sputum induction and to investigate the repeatability of
cell counts, £uid phase mediators, symptom scores and
the chronic respiratory disease questionnaire measured
2 weeks apart in a group of patients with moderate and
severe COPD.
METHODS
Subjects
Subjects had partaken in a randomized,
placebo-controlled, cross-over trial of 2 weeks of
prednisolone or placebo (15). Data from the placebo
arm of this trial was used to assess safety of sputum
induction and repeatability of outcomemeasures.
Subjects were recruited from respiratory clinics
with symptoms of chronic air£ow obstruction and a
post-bronchodilator FEV1 of o70% predicted and FEV1
forced vital capacity (FVC) ratio ofo70%.Therewas no
signi¢cant improvement in FEV1 after 2?5 mg nebulized
salbutamol (o15%, or if FEV1o1?2 l o200 ml
improvement). Subjects were excluded if they had a
clinical diagnosis of asthma, a history of childhood
respiratory problems, variability in symptoms not
associated with infections, a history of acute wheeze,
breathlessness or deterioration associated with
allergens or an exacerbation within 6 weeks of trial
entry. Subjects had not taken oral or inhaled
corticosteroids for at least 1 month. The study was
approved by the local research ethics committee and all
subjects gavewritten informed consent.
Study design
Subjects attended for sputum induction before and
4^6 h after the last dose of placebo at the same time of
day on each occasion more than 6 h after their last dose
of bronchodilator and 24 h after the last dose of
long-acting b2-agonists.
Measurements
Details of the subject’s smoking, treatment and
childhood respiratory history was obtained. Spirometrywas performedwith a Compact Vitalograph spirometer
(Vitalograph, Buckinghamshire, U.K.). Salbutamol was
administered via a Flaem NuovaType II nebulizer (Deva
Medical, Runcorn,Cheshire,U.K.) with a median particle
size 2 mm and the patient breathing tidally. FEV1 was
recorded as the better of two successive readingswithin
100 ml. Pulmonary function tests were performed using
a PK Morgan Benchmark (Chatham, U.K.) and lung
volumes were assessed using the helium dilution
method.
Symptom scores were recorded using a100 mmvisual
analogue scale (VAS) from no symptom to the worst
symptom ever for dyspnoea, cough, sputum production
andwheeze.Health statuswas assessedusing the chronic
respiratory disease questionnaire (CRQ), consisting of 20
questions measuring four domains: dyspnoea, fatigue,
emotions and mastery. A seven-point Likert scale was
used for each question and the total CRQ and each do-
main scorewas recorded out of seven (11).
Sputum was induced and processed as previously
described (6,16). Brie£y, sputum was induced using 3, 4
and 5% saline inhaled in sequence for 5 min each via a
low output (0?9 mlminÿ1, median particle size 5 mm)
ultrasonic nebulizer (Medix, Harlow, U.K.), 30 min after
nebulized salbutamol 2?5 mg. Sputum induction was
not performed in subjects with an FEV1o0?5 l. The fall
in FEV1during sputum inductionwasmeasured from the
post-bronchodilator FEV1. Expectorated sputum was
stored on ice and analysed within 2 h of expectoration.
A di¡erential cell count was obtained by counting
4400 non-squamous cells on Romanovski-stained
cytospins.
Sputum elastase was measured in the cell free
supernatant using a spectro£uorimetric assay (15). IL-8
was measured using a commercial enzyme linked immu-
nosorbent assay (OptE1A Set, Pharmingen, U.K.) and
eosinophilic cationic protein (ECP) was measured using
a commercial £uroimmunoassay (Unicap, Pharmacia,
Milton Keynes. U.K.). The limits of detection for the
elastase, IL-8 and ECP were 1?5 mg gÿ1, 30 pg gÿ1 and
18 ng gÿ1of sputum respectively.
Analysis
Descriptive statistics were used for subject
characteristics. Spirometry, per cent fall in FEV1,
symptom scores, total CRQ and CRQ domains were
described asmean and standard error of themean (SEM).
Eosinophil count, total cell count and mediator
concentrations were log normally distributed and were
described as geometric mean (log SEM). Other sputum
di¡erential cell counts were reported as the mean
(SEM). Repeatability was described as the within-subject
standard deviation of the di¡erence between duplicate
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themeasures.
RESULTS
Safety of sputum induction
Subject characteristics are shown in Table 1. Sputum
induction was performed on 122 occasions and was
successful resulting in a cytospin adequate to assess a
di¡erential cell count in 95% of inductions. The mean
(SEM) fall in FEV1 after sputum induction was 120 ml (6)TABLE 1. Subjectcharacteristics
Numberof subjects 61
Age* 66 (13)
Male 37
Current smokers 15
Pack years* 30 (10)
FEV1(1)
w 1?09 (0?05)
FEV1post-bronchodilator (1)
w 1?14 (0?06)
FEV1 (% predicted)
w 41?6 (2?9)
FEV1/FVCratio (%)
w 48?2 (3?1)
TLC (% predicted)w 95 (3?8)
RV/TLC (% predicted)w 122 (7?2)
KCO (% predicted)w 87 (7?9)
*Median (IQR), wMean (SEM).
TABLE 2. Within-subject repeatabilityof outcomemeasures
Visit1
Neutrophil (%)w 74 (2?5)
Eosinophil (%)* 2?2 (0?09)
Macrophage (%)w 22 (2?5)
Lymphocyte (%)w 0?3 (0?05)
Epithelial cells (%)w 1?0 (0?16)
TCC106 gÿ1sputum* 2?7 (0?04)
ECPng gÿ1* 1149 (0?09) 1
IL-8 ng gÿ1* 112 (0?08)
Elastase mgmlÿ1* 42?5 (0?11)
CRQ:Totalw 4?03 (0?14)
CRQ:Dyspnoeaw 3?52 (0?16)
CRQ:Fatiguew 3?72 (0?17)
CRQ:Emotionw 4?46 (0?17)
CRQ:Masteryw 48?61 (0?18)
VAS:Dyspnoea (mm)w 48?2 (3?2)
VAS:Wheeze (mm)w 32?1 (3?6)
VAS:Cough (mm)w 32?4 (4?6)
VAS:Sputum (mm)w 26?8 (3?0)
*Geometricmean (log SEM), wmean (SEM).and % fall 10?9% (0?55). There was no signi¢cant
di¡erence between the mean (SEM) % fall after the ¢rst
11?2% (0?7) or second 10?7% (0?8) induction (mean
di¡erence 0?45, 95% CI^1?4, 2?3; P=0?6) and the
intra-class correlation coe⁄cientwas 0?32. Seven induc-
tions were complicated by a fall in FEV1420%, four of
which were two subjects who had a signi¢cant fall in
their FEV1 following both inductions. On a further 13
occasions the full sputum induction protocol was not
completed due to development of symptoms: dyspnoea
in six and nausea or general discomfort in seven.
Repeatability of outcomemeasures
There were no signi¢cant di¡erences between the
di¡erential cell counts, total cell count, symptom scores
or CRQ total and domains before and after placebo.The
repeatability of themeasures are shown onTable 2.
DISCUSSION
Wehave shown that sputuminductionusing a lowoutput
nebulizer is well tolerated, safe and successful in patients
with moderate and severe COPD.The reproducibility of
the sputum cell counts and £uid phase mediators was
relatively high for all indices measured with the
exception of the proportion of lymphocytes and epithe-
lial cells.Visit 2 Within-subject SD ICC
69 (2?7) 17?8 0?57
2?1 (0?13) 0?66 0?63
3 (2?4) 16?4 0?54
0?7 (0?25) 1?95 0?15
1?5 (0?35) 2?8 0?32
2?6 (0?05) 0?31 0?54
236 (0?09) 0?48 0?70
97 (0?1) 0?62 0?71
36?5 (0?11) 1?07 0?4
4?08 (0?14) 0?18 0?95
3?44 (0?17) 0?33 0?91
3?77 (0?16) 0?33 0?90
4?6 (0?17) 0?22 0?96
4?59 (0?19) 0?26 0?94
48?0 (3?2) 4?82 0?94
31?8 (3?5) 8?62 0?87
33?5 (3?4) 7?75 0?87
27?5 (3?1) 4?82 0?94
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to that reported in normal and asthmatic subjects (6).
The poor repeatability of the lymphocyte cell count
has been noted before in asthma and probably
re£ects the di⁄culty in the accurate recognition of this
cell type and their scarcity in induced sputum (17). To
investigate this aspect of the in£ammatory response
bronchoalveolar lavage and biopsy would be more
appropriate. Our ¢ndings show that the assessment of
induced sputum markers of neutrophilic airway
in£ammation is feasible and repeatable in subjects with
moderate and severe COPD.
We have previously established that sputum induction
is safe in asthma (5). In this current study 94% of
inductions were associated with a fall in FEV1o20% and
the mean FEV1 fall was10?9%.This is broadly in line with
the mean % fall we have observed in asthma (5) and
similar to the10?7% (8) and11?7% (9) fall reported in two
previous studies using a higher output nebulizer in
COPD. The fall in FEV1 was similar after both sputum
inductions andwasbroadlyrepeatable. Although sputum
induction can lead to a signi¢cant fall in lung function and
symptoms in some patients these ¢ndings con¢rm that
when performed carefully with frequent assessment of
lung function, sputum induction is safe even in patients
withmoderate to severe air£ow obstruction.
In keeping with previous reports we con¢rm that the
CRQ is a reproducible outcomemeasure of health status
in COPD (11,12).We have also established that symptom
visual analogue scores are repeatable outcome
measures. In the associated intervention study we found
that symptom VAS were amongst the most responsive
measures following prednisolone treatment (15). This,
coupled with the ease of administration and excellent
repeatability, suggests that they are particularly useful
outcomemeasures.
Our study was not primarily designed to assess the
repeatability of sputummarkers of airway in£ammation,
health status and symptom scores and we can not
exclude a possible bias due to the placebo e¡ect.
However, no placebo e¡ect was observed on spiro-
metry, health status or symptoms (15) and we consider
it unlikely that the placebo medication would have
in£uenced the e¡ect of sputum induction on lung func-
tion or airway in£ammation. Ideally further studies
should assess repeatability of these measures in
untreated stable patients. In the absence of such data
our study does at least provide an estimate of the
between andwithin subject variability.
In conclusion we have shown that sputum induction is
safe and successful in subjects withmoderate and severe
COPD and that sputum cell counts, £uid phase
mediators, CRQ scores and VAS symptom scores are
repeatable outcome measures in COPD. Our ¢ndings
will help other investigators plan and power future
intervention studies.Acknowledgements
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